Dr Roy: Phase 2 trial of selective depletion of recipient-alloreactive T-cells (ATIR) in AML and ALL

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Denis-Claude Roy (University of Montreal, Montreal, Canada) discusses a phase II trial that evaluated selective photodepletion of recipient-alloreactive T-cells (ATIR) for haploidentical haematopoietic stem cell transplant in patients with acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). ATIR does not cause any grade III/IV graft-versus-host disease (GvHD) and demonstrates promising treatment-related mortality and overall survival rates.

Year of Production:
Running Time:


Comments are closed.